Info from the

New Post Public Reply Private Reply Replies (1) Message Board
TedJ
439
Info from the FDA:

https://www.fda.gov/medical-devices/emergency...2#serology

Quote:
Serology/Antibody Test FAQs
Q: Are antibody, or serology, tests used to diagnose SARS-CoV-2 infection? (Updated 5/4)
A: The terms "serological" or "antibody" tests are generally used to refer to tests that detect antibodies to the SARS-CoV-2 virus. Because the antibodies are part of the body's immune response to exposure and not the virus itself, such testing cannot be used for diagnosis of infection. Based on the underlying scientific principles of antibody tests, we do not expect that an antibody test can be shown to definitively diagnose or exclude COVID-19 infection. SARS-CoV-2 antibody tests are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection, by detecting antibodies to SARS-CoV-2 in human blood specimens.

As stated in the Policy for Coronavirus Disease-2019 Tests, validated antibody tests offered under the policy in that guidance should, among other things, include in instructions for use and test reports information to convey that negative results do not preclude acute SARS-CoV-2 infection and that, if acute infection is suspected, direct testing for SARS-CoV-2 is necessary. SARS-CoV-2 serology tests should be ordered only by clinicians who are familiar with the use and limitations of the test.

Quote:
Q: If antibody tests are not used for diagnosis or exclusion of COVID-19 infection, what is their purpose? (Updated 5/4)
A: Serology (antibody) tests may detect different types of antibodies. The most common are IgM and IgG. High quality serological tests can help us understand whether a person or population of people have developed antibodies indicative of an adaptive immune response to COVID-19.

Because a serology test can yield a negative test result even in infected patients (e.g., if antibody has not yet developed in response to the virus) or may be falsely positive (e.g., if antibody to a coronavirus type other than the current pandemic novel strain is present), antibody tests should not be used in the immediate diagnosis of a patient where COVID-19 infection is suspected. That is, these tests should not be used to diagnose acute COIVD-19 infection. Using this type of test on many patients may help the medical community better understand how the immune response against the SARS-CoV-2 virus develops in patients over time and how many people may have been infected. While there is a lot of uncertainty with this new virus, it is also possible that, over time, broad use of antibody tests and clinical follow-up will provide the medical community with more information on whether or not, and how long, a person who has recovered from the virus is at lower risk of infection if they are exposed to the virus again.

Positive results from appropriately validated serology tests that are designed to be very specific to the SARS-CoV-2 virus can indicate whether a patient has had recent or prior COVID-19 infection. In addition, although not everyone who is infected will develop an antibody response, appropriately validated serology tests, when used broadly, can be useful in understanding how many people have developed an adaptive immune response to the virus and how far the pandemic has progressed.

Serology tests can play a critical role in the fight against COVID-19 by helping healthcare professionals identify individuals who have antibodies to SARS-CoV-2 virus and have developed an adaptive immune response. In the future, this may potentially be used to help determine, together with other clinical data, whether these individuals may be less susceptible to infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. In addition, these test results can aid in determining who may be eligible to donate a part of their blood called convalescent plasma, which may serve as a possible treatment for those who are seriously ill from COVID-19.

Quantum Materials Corp. (QTMM) Stock Research Links

QTMM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 120

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 117

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Segway Powersports Ventures into Baja 1000: Ambitions Run High

Updated Category News Views 20

They're gunning for glory in the sands of Baja, folks—Segway Powersports is about to rev up the excitement with its Baja 1000 debut. Never heard before in this legendary race's chronicles, Segway aims to shake up the game with their two brawny Super Villain UTVs. These aren't your run-of-the-pavement ride-ons; they're built for the rough stuff—and if there's a stage...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 439

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cars.com Inducement Awards: New CPO Earns Stock Boost

Updated Category News Views 57

Revving Up With Incentives: A Strategic Move by Cars.com Ever seen a stock maneuver that feels more like a chess play than a plain deal? On November 5, 2026, Cars.com (NYSE: CARS) fired up quite a strategic engine. They handed out a heap of restricted stock units—373,345 to be precise—to Mausam Bhatt, freshly minted as their Chief Product Officer. This isn't just your...

Continue Reading
Tencent Cloud's Edge Platform Shines in New Gartner Report

Updated Category News Views 24

The Breakthrough in Edge Computing Everyone's talking about cloud this and cloud that, but Tencent Cloud is taking things a notch further with its EdgeOne platform. It's not just about storing your files in the sky; it's about having the fastest, most secure delivery possible. Gartner's latest report puts these guys right at the top in their Magic Quadrant for Edge...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 322

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 417

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 302

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 147

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading

Top 5 Most Recently Viewed Articles

Verint's Investor Day: Unveiling Key Innovations in CX Automation

Updated Category News Views 254

Exciting Updates from Verint's Investor Day Event Verint® (Nasdaq: VRNT), known as The CX Automation Company™, has recently held its much-anticipated Investor Day, highlighting significant advancements and outlined strategies aimed at shaping the future of customer experience (CX). The event kicked off with CEO Dan Bodner expressing enthusiasm about discussing the...

Continue Reading
Tri Pointe Homes, Inc. Delivers Strong Q3 2025 Performance

Updated Category News Views 255

Tri Pointe Homes Reports Outstanding Third Quarter Performance Tri Pointe Homes, Inc. (NYSE: TPH), a leading homebuilder in America, has unveiled strong results for the third quarter of 2025, highlighting significant achievements in home deliveries and financial performance. Key Highlights of Q3 2025 The company has reported a total of 1,217 new home deliveries during...

Continue Reading
Main Street Capital Q3 2024 Results Showcase Strong Growth

Updated Category News Views 144

Main Street Capital Reports Impressive Financial Results Main Street Capital Corporation (NYSE: MAIN) is excited to share its financial results for the third quarter of 2024. With solid performance reflected in higher net investment income and a robust capital position, the company demonstrates its commitment to delivering value to shareholders. Highlights from Q3 2024...

Continue Reading
Rathbones Group Plc's Significant Position in Warpaint London

Updated Category News Views 194

Key Disclosure of Rathbones Group Plc In the financial landscape, transparency is of utmost importance, especially when significant interests in securities come to light. Rathbones Group Plc has provided a crucial disclosure as they maintain an interest in relevant securities of Warpaint London Plc, representing over 1% of their shares. This type of disclosure aligns with...

Continue Reading
Anticipated Surge in Electric Trucks Market to $20.32 Billion

Updated Category News Views 149

Overview of the Electric Trucks Market Growth The global electric trucks market is projected to witness significant growth, with estimates indicating an increase of USD 20.32 billion from recent years through to 2028. This growth trajectory shows an impressive compound annual growth rate (CAGR) of approximately 35.44%. The rising demand for fuel-efficient and low-emission...

Continue Reading